Evidence map›Paper›PMID 40790495›Full record

ReviewJournal of translational medicine2025

A review of C/EBP α: a potential novel target for solid tumor intervention.

Xin Li, Tengkun Dai, Jiamin Zhao, Yidan Liang, Longqing Chen, Chao Chen, Mengmeng Guo, Yong Han, Lin Xu, Juanjuan Zhao

Abstract readReview
In one paragraph

Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xin LiDepartment of Immunology, Zunyi Medical University, Zunyi, 563000, China.
Tengkun DaiDepartment of Immunology, Zunyi Medical University, Zunyi, 563000, China.
Jiamin ZhaoDepartment of Immunology, Zunyi Medical University, Zunyi, 563000, China.
Yidan LiangDepartment of Immunology, Zunyi Medical University, Zunyi, 563000, China.
Longqing ChenKey Laboratory for Cancer Prevention and treatment of Guizhou Province, Guizhou Zunyi, 563000, China.
Chao ChenDepartment of Immunology, Zunyi Medical University, Zunyi, 563000, China.
Mengmeng GuoDepartment of Immunology, Zunyi Medical University, Zunyi, 563000, China.
Yong HanKey Laboratory for Cancer Prevention and treatment of Guizhou Province, Guizhou Zunyi, 563000, China.
Lin XuDepartment of Immunology, Zunyi Medical University, Zunyi, 563000, China. xulinzhouya@163.com.
Juanjuan ZhaoDepartment of Immunology, Zunyi Medical University, Zunyi, 563000, China. jj.z.2008@163.com.

Funding

National Natural Science Foundation of China 32160178National Natural Science Foundation of China 82272812
6 · The paper itself

Abstract

C/EBPα (CCAAT enhancer binding protein) is a pivotal transcription factor with widespread expression in multiple tissues, including hematopoietic tissues, liver, lungs, mammary glands, skin, and adipose tissue. It plays a significant role in the developmental regulation of these tissues. Previous research has primarily concentrated on C/EBPα's involvement in the hematological system, particularly its role in maintaining human hematopoietic stem cell homeostasis and regulating myeloid differentiation. Notably, recent studies have revealed that C/EBPα is instrumental in the development and therapeutic targeting of solid tumors. Abnormal expression of C/EBPα has been observed in various tumor types, such as liver, breast, pancreatic, gastric, and lung cancers, where it regulates tumor cell proliferation, differentiation, and other processes through signaling pathways including EGFR/β-catenin, Wnt, and so on. Moreover, the expression levels of C/EBPα are closely associated with the clinical prognosis of these solid tumors. These findings suggest that C/EBPα may serve as a promising new target for clinical interventions against solid tumors. In this paper, we systematically review the structure, function, and expression regulation mechanism of C/EBPα. We also discuss its biological functions in solid tumors such as breast, liver, and pancreatic cancers, along with key scientific issues that need to be addressed in future studies, our aim is to provide new perspectives and robust support for the in-depth elucidation of the biological function of C/EBPα, and for the development of new strategies for the clinical treatment of solid tumors.

Indexed as

CCAAT-Enhancer-Binding Protein-alphaMolecular Targeted TherapyNeoplasmsAnimalsGene Expression Regulation, NeoplasticHumansSignal TransductionCCAAT-Enhancer-Binding Protein-alphaC/EBPαGene expressionSolid tumorsTherapeutic targetsTranscriptional modification

Identifiers

PMID40790495
PMCPMC12341345

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.